Massey sac fly in 10th gives Royals 3-2 win over Rays

Peter Aiken-USA TODAY Sports
1 Comment

ST. PETERSBURG, Fla. – Michael Massey‘s sacrifice fly in the 10th inning lifted Kansas City to a 3-2 win over the Tampa Bay Rays on Friday night, ending the Royals’ four-game skid.

Massey drove in automatic runner Michael A. Taylor, who had moved up to third on a groundball.

Scott Barlow (5-4) got the win in relief with help from catcher Salvador Perez, who threw out Roman Quinn on an attempted steal of third in the 10th. MJ Melendez, who had thrown out Taylor Walls attempting to stretch a single into a double for the first out in the 10th, ended the game with a diving catch of Francisco Mejia’s sinking liner in left field.

Jalen Beeks (2-3) took the loss for the Rays, who have won five of seven and are in position for an AL wild card.

Bobby Witt’s 16th home run put the Royals up 2-0 in the third against Rays starter Shane McClanahan. But Kansas City got only one other runner as far as second base until Taylor started the 10th there.

Witt’s homer came after a walk to Melendez and was the first of only two hits McClanahan allowed in seven innings. McClanahan walked three and struck out eight.

Royals starter Brady Singer gave up two runs on five hits and four walks in six innings, striking out seven.

Randy Arozarena drove in Tampa Bay’s first runs with a two-out single in the sixth after hits by David Peralta and Harold Ramirez.

Singer picked Ramirez off second base with two out and the bases loaded in the third.

TRAINER’S ROOM

Rays: OF Manuel Margot, out since June 21 with a right patellar tendon strain, is eligible to come off the 60-day injured list Saturday. … RHP J.P. Feyereisen, who last pitched on June 2 due to a right shoulder impingement, said he hopes to return in September. … Tampa Bay selected RHP Kevin Herget from Triple-A Durham and optioned RHP Luis Patino to Durham.

UP NEXT

RHP Drew Rasmussen (7-4, 2.80 ERA), who took a perfect game into the ninth inning against Baltimore on Sunday, will start Saturday for the Rays against LHP Kris Bubic (2-7, 5.11).

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.